OTCMKTS:CXRXF ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free CXRXF Stock Alerts $17.06 0.00 (0.00%) (As of 06/10/2021) Add Compare Share Share Today's Range$17.06▼$17.0650-Day Range$17.06▼$17.0652-Week Range$2.13▼$18.00Volume39 shsAverage Volume11,851 shsMarket Capitalization$834.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ADVANZ PHARMA alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About ADVANZ PHARMA Stock (OTCMKTS:CXRXF)ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Read More CXRXF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CXRXF Stock News HeadlinesApril 7, 2024 | seekingalpha.comPHAT Phathom Pharmaceuticals, Inc.March 12, 2024 | msn.comDimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trialApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinFebruary 28, 2024 | msn.comInterim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024November 7, 2023 | msn.comDimerix receives $10.7 million upfront payment from Advanz PharmaJanuary 4, 2023 | msn.comApplied Therapeutics adds 19% on partnership with Advanz Pharma for lead assetSeptember 27, 2022 | dallasnews.comMADE in America Act is critical for the pharmaceutical industryAugust 5, 2022 | seekingalpha.comPolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in EuropeApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinJuly 1, 2022 | benzinga.comIntercept Announces Closing of Transaction with Advanz Pharma to Transfer Rights to Commercialize Ocaliva® for PBC Outside the U.S.May 5, 2022 | seekingalpha.comIntercept Pharma to sell ex-U.S. rights for Ocaliva to Advanz PharmaSee More Headlines Receive CXRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:CXRXF CUSIPN/A CIKN/A Webwww.advanzpharma.com Phone44-20-8588-9100FaxN/AEmployees429Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,860,000.00 Net Margins-15.31% Pretax MarginN/A Return on EquityN/A Return on Assets-4.38% Debt Debt-to-Equity Ratio257.04 Current Ratio2.39 Quick Ratio1.61 Sales & Book Value Annual Sales$525.58 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book106.63Miscellaneous Outstanding Shares48,913,000Free FloatN/AMarket Cap$834.46 million OptionableNot Optionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Graeme Neville Duncan (Age 46)CEO & Exec. Director Comp: $1.26MMr. Adeel Ahmad (Age 46)CFO & Exec. Director Comp: $752.73kMr. Karl Ian Belk (Age 52)Chief Operations Officer Comp: $685.79kMr. Robert Sully (Age 47)Gen. Counsel Comp: $669.75kMr. Paul Burden (Age 46)Chief Commercial Officer of Strategic Growth Unit Comp: $638.96kMr. Adam PeelerVP of Investor Relations & CommunicationsMr. Guy Clark (Age 50)Chief Corp. Devel. Officer Mr. Arijit MookerjeeMD and CFO of CPI & CLIMr. Andrew Patrick HoytChief Financial Officer of US Bus.esMr. Robert D. Ford (Age 54)MD & Sr. Director of Legal Affairs of CPI and CLI More ExecutivesKey CompetitorsTango TherapeuticsNASDAQ:TNGXArcutis BiotherapeuticsNASDAQ:ARQTARS PharmaceuticalsNASDAQ:SPRY89bioNASDAQ:ETNBEnliven TherapeuticsNASDAQ:ELVNView All Competitors CXRXF Stock Analysis - Frequently Asked Questions How have CXRXF shares performed in 2024? ADVANZ PHARMA's stock was trading at $17.06 at the start of the year. Since then, CXRXF shares have increased by 0.0% and is now trading at $17.06. View the best growth stocks for 2024 here. How do I buy shares of ADVANZ PHARMA? Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CXRXF) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADVANZ PHARMA Corp. Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.